Thymosin Alpha-1 Dosage: Doses Studied, Units and Chart
What doses of Thymosin Alpha-1 have been used in published research, how they convert to syringe units, and what is still unknown.
- Doses studied
- 9 studies
- with a stated dose, listed below
- Frequency
- Varies by study
- as used in studies
- Half-life
- elimination half-life less than 3 hours; Tmax 1-2 hours
- subcutaneous, in people · International journal of clinical pharmacology and therapeutics 1999, PMID 10027483
Doses used in published studies
Each dose below is quoted from a study abstract, strongest design first. Animal doses are labelled and do not translate directly to people. None of them is a recommendation.
| Dose | Frequency and route | Study type | Source |
|---|---|---|---|
| not stated in abstract | every 12 hours · subcutaneous · seven days | Human RCTn = 1106 | BMJ 2025, PMID 39814420 |
| 3.2 mg | twice per day · injection · 7 days | Human RCTn = 24 | Inflammation 2011, PMID 20549321 |
| 1.6 mg | 5 times weekly · SC · 24 weeks | Human RCTn = 25 | Hepatology international 2009, PMID 19669251 |
| 0.8 mg or 1.6 mg | six times weekly for two weeks, then twice weekly · not stated · 24 weeks | Human RCTn = 16 | Internal medicine 2003, PMID 14606705 |
| 900 microg/m2 | single dose and 5-day multiple dose · subcutaneous | Human RCTn = 9 | International journal of clinical pharmacology and therapeutics 1999, PMID 10027483 |
| 900 microg/m2 body surface area | twice weekly · subcutaneous (injection) · 6 months | Human RCTn = 33 | Hepatology 1996, PMID 8855175 |
| 900 micrograms/m2 body surface area | twice weekly · injection (route not stated) · 6 months | Human RCTn = 19 | Liver 1996, PMID 8873009 |
| 1.6 mg | qd or q12 h · not stated · more than 5 days | Human observationaln = 334 | International immunopharmacology 2020, PMID 32795897 |
| 1.6 mg (with IFN alpha 2a 3 mU) | twice a week · s.c. · 52 weeks | Human uncontrolled trialn = 12 | Journal of the Medical Association of Thailand = Chotmaihet thangphaet 2001, PMID 11529376 |
Before anyone considers it
- Thymosin Alpha-1 is not FDA approved for any use.
- Products sold as research chemicals are not checked by the FDA for identity, purity or dose.
- Reconstitution math (mg vs mcg, units vs mL) is the most asked question in peptide forums. Check every number twice.
- People who are pregnant, breastfeeding, or have a chronic condition need medical advice first.
Regimens in small randomised trials
A pilot trial randomised patients to 0.8 mg or 1.6 mg of thymosin alpha 1, given as an initial phase followed by twice-weekly doses for another 22 weeks.[6]
The low and high groups did not differ significantly (p = 0.608).[6]
A phase II liver-cancer trial used 1.6 mg subcutaneously, 5 times weekly, for 24 weeks alongside chemoembolization.[5]
In severe acute pancreatitis the regimen was 3.2 mg twice per day for 7 days.[4]
Pharmacokinetics
A 9-volunteer crossover compared three formulations at 900 microg/m2 subcutaneously, reporting a short elimination half-life of less than 3 hours.[7]
Status
Drugs@FDA returned no thymalfasin match, so no US label sets a regimen.[12]
Common questions
Is Thymosin Alpha-1 FDA approved?
No. Thymosin Alpha-1 is not FDA approved for any use.
What is the thymosin alpha 1 dosing in studies?
One trial design is 1.6 mg subcutaneously 5 times weekly for 24 weeks, alongside chemoembolization in liver cancer.[5]
Is there a thymosin alpha 1 dosage chart or protocol?
The cleanest comparison in the cached set is the hepatitis B pilot, which randomised 0.8 mg against 1.6 mg.[6]
More on Thymosin Alpha-1
Sources
- 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
- 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
- 3The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial.BMJ (Clinical research ed.) · 2025PMID 39814420Accessed 2 Oct 2026
- 4Thymosin alpha 1 is associated with improved cellular immunity and reduced infection rate in severe acute pancreatitis patients in a double-blind randomized control study.Inflammation · 2011PMID 20549321Accessed 2 Oct 2026
- 5A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma.Hepatology international · 2009PMID 19669251Accessed 2 Oct 2026
- 6A pilot study of thymosin alpha1 therapy for chronic hepatitis B patients.Internal medicine (Tokyo, Japan) · 2003PMID 14606705Accessed 2 Oct 2026
- 7Pharmacokinetics of thymosin alpha1 after subcutaneous injection of three different formulations in healthy volunteers.International journal of clinical pharmacology and therapeutics · 1999PMID 10027483Accessed 2 Oct 2026
- 8Thymosin α1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study.International immunopharmacology · 2020PMID 32795897Accessed 2 Oct 2026
- 9A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody--and hepatitis B virus DNA--positive chronic hepatitis B.Hepatology (Baltimore, Md.) · 1996PMID 8855175Accessed 11 Oct 2026
- 10A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C.Liver · 1996PMID 8873009Accessed 11 Oct 2026
- 11The combined treatment of interferon alpha-2a and thymosin alpha 1 for chronic hepatitis C: the 48 weeks end of treatment results.Journal of the Medical Association of Thailand = Chotmaihet thangphaet · 2001PMID 11529376Accessed 11 Oct 2026
- 12Drugs@FDA (openFDA) search: active ingredient "thymalfasin"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.